The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Open accessAbstract
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by our group (9, 17-20) and others (7, 21, 22) have demonstrated a strong relationship between triglyceride content in liver and muscle and insulin resistance in these tissues.”
From Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (2002) · cites this paper as [9]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Thiazolidinediones, which are potent PPARγ agonists, can effectively reduce hepatic steatosis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Moreover, reductions in intracellular diacylglycerol content account for the improvements in insulin sensitivity after weight loss81 and therapy with thiazolidinediones.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“The TZDs improve insulin resistance by increasing glucose disposal in muscle and decreasing hepatic glucose output.26”
From A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (2004) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citationDENSITOMETRIC ANALYSIS OF BODY COMPOSITION: REVISION OF SOME QUANTITATIVE ASSUMPTIONS*
Brožek, J., Grande, F., Anderson, J. T., & Keys, A. B. (1963) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1963.tb17079.x · Cited by 2,263
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Self-citationDresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Self-citationGriffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Self-citationKrssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Shulman, G. I., & Roden, M. (1999) · Diabetologia · doi:10.1007/s001250051123 · Cited by 1,264
Self-citation
Cited by
Sorted by citations
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Self-citationPPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Szczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,573
Metadata
- Authors
- Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F.
- Affiliations
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 797-802
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2995527
- OpenAlex
- W2100514340
- Cited by
- 647
- References
- 53
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 11 · 2023: 15 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 20 · 2018: 12 · 2017: 15 · 2016: 15 · 2015: 22 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 24.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- Deutsches Krebsforschungszentrum
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01DK049230, R01 DK-49230, K23DK002734, P30DK045735)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- rosiglitazone, thiazolidinediones, type 2 diabetes, insulin sensitivity, hepatic triglyceride content, extramyocellular lipids, plasma fatty acids, hyperinsulinemic-euglycemic clamp, microdialysis, lipid redistribution
- MeSH terms
- Rosiglitazone, Adipose Tissue, Blood Glucose, Body Composition, Calorimetry, Indirect, Diabetes Mellitus, Type 2, Fatty Acids, Glycerol, Glycated Hemoglobin, Humans, Hyperinsulinism, Insulin, Kinetics, Lipids, Lipolysis, Liver, Middle Aged, Magnetic Resonance Spectroscopy, Oxidation-Reduction, Thiazoles, Triglycerides, Glucose Clamp Technique, Microdialysis, Adipocytes, Muscle, Skeletal, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
